Vorozole, a specific non-steroidal aromatase inhibitor

Area of Science:

• Endocrinology
• Pharmacology
• Oncology

Background:

• Aromatase enzymes are crucial for estrogen biosynthesis.
• Estrogen plays a significant role in the growth of hormone-dependent mammary tumors.
• Selective aromatase inhibitors are valuable therapeutic agents for hormone-sensitive cancers.

Purpose of the Study:

• To evaluate the efficacy and selectivity of Vorozole, a novel triazole compound, as an aromatase inhibitor.
• To assess the in vitro and in vivo activity of Vorozole in preclinical models.
• To investigate the effects of Vorozole on tumor growth and hormone levels in relevant models.

Main Methods:

• In vitro enzyme inhibition assays to determine potency and selectivity against aromatase.
• In vivo studies in a rat model of DMBA-induced mammary carcinoma.
• Pharmacokinetic profiling including oral bioavailability and dose proportionality.
• Hormone level measurements (estradiol, adrenal corticoids) in preclinical and clinical settings.

Main Results:

• Vorozole demonstrated over 1000-fold greater in vitro potency than aminoglutethimide.
• High selectivity for aromatase inhibition (10,000-fold) was observed in vitro and confirmed in vivo.
• Vorozole significantly reduced mammary tumor growth in rats, comparable to ovariectomy.
• In postmenopausal women, Vorozole effectively reduced peripheral conversion of androstenedione to estrone, lowering estradiol levels without impacting adrenal steroids.
• Vorozole exhibited excellent oral bioavailability and linear pharmacokinetics.

Conclusions:

• Vorozole is a highly potent and selective aromatase inhibitor.
• Vorozole demonstrates significant efficacy in reducing hormone-dependent tumor growth.
• The drug is well-tolerated, with favorable pharmacokinetic properties and no adverse effects on adrenal steroidogenesis.